This study is being conducted to evaluate the safety and effectiveness of two experimental medications, EXV-802 and EXV-801, for treating agitation in individuals living with Alzheimer’s disease dementia. Agitation refers to feelings of restlessness, irritability, or anxious behavior that can occur in people with this type of memory-related brain disorder. The medication EXV-802 contains a combination of dextromethorphan and deramciclane fumarate, while EXV-801 contains deramciclane. Participants in the study may receive one of these active treatments or a placebo.

The study follows a double-blind design, which means that neither the participants nor the researchers know who is receiving the active medication and who is receiving the placebo. This method is used to prevent bias in the results. During the course of the study, participants will take an oral capsule for a period of time to monitor how the medications affect their symptoms and general well-being.